| Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial DA Palma, R Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, L Mulroy, ... The Lancet 393 (10185), 2051-2058, 2019 | 1680 | 2019 |
| Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis S Senthi, FJ Lagerwaard, CJA Haasbeek, BJ Slotman, S Senan The lancet oncology 13 (8), 802-809, 2012 | 519 | 2012 |
| Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review S Senthi, CJA Haasbeek, BJ Slotman, S Senan Radiotherapy and Oncology 106 (3), 276-282, 2013 | 288 | 2013 |
| Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial DA Palma, R Olson, S Harrow, RJM Correa, F Schneiders, CJA Haasbeek, ... BMC cancer 19, 1-15, 2019 | 211 | 2019 |
| Oral health, academic performance, and school absenteeism in children and adolescents: A systematic review and meta-analysis RR Ruff, S Senthi, SR Susser, A Tsutsui The Journal of the American Dental Association 150 (2), 111-121. e4, 2019 | 147 | 2019 |
| High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer K Huang, S Senthi, DA Palma, FOB Spoelstra, A Warner, BJ Slotman, ... Radiotherapy and Oncology 109 (1), 51-57, 2013 | 144 | 2013 |
| Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial DA Palma, RA Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, ... International Journal of Radiation Oncology, Biology, Physics 102 (3), S3-S4, 2018 | 119 | 2018 |
| Quality of life outcomes after stereotactic ablative radiation therapy (SABR) versus standard of care treatments in the oligometastatic setting: a secondary analysis of the … R Olson, S Senan, S Harrow, S Gaede, A Louie, C Haasbeek, L Mulroy, ... International Journal of Radiation Oncology* Biology* Physics 105 (5), 943-947, 2019 | 57 | 2019 |
| The normal tissue effects of microbeam radiotherapy: What do we know, and what do we need to know to plan a human clinical trial? LML Smyth, S Senthi, JC Crosbie, PAW Rogers International journal of radiation biology 92 (6), 302-311, 2016 | 53 | 2016 |
| Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised … MT King, EK Link, TJ Whelan, IA Olivotto, I Kunkler, AH Westenberg, ... The Lancet Oncology 21 (5), 685-698, 2020 | 52 | 2020 |
| Radiotherapy for a second primary lung cancer arising post-pneumonectomy: planning considerations and clinical outcomes S Senthi, CJA Haasbeek, FJ Lagerwaard, WF Verbakel, PF de Haan, ... Journal of thoracic disease 5 (2), 116, 2013 | 30 | 2013 |
| Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: a comparison of fixed-beam versus arc delivery techniques S Senthi, M Dahele, PM van de Ven, BJ Slotman, S Senan Radiotherapy and Oncology 109 (1), 77-81, 2013 | 29 | 2013 |
| Comparing rigid and deformable dose registration for high dose thoracic re-irradiation S Senthi, GHMJ Griffioen, JRVS De Koste, BJ Slotman, S Senan Radiotherapy and Oncology 106 (3), 323-326, 2013 | 28 | 2013 |
| Surgery versus SABR for NSCLC AV Louie, S Senthi, DA Palma The Lancet Oncology 14 (12), e491, 2013 | 23 | 2013 |
| Reducing posttreatment dysphagia: support for the relationship between radiation dose to the pharyngeal constrictors and swallowing outcomes J Frowen, C Hornby, M Collins, S Senthi, R Cassumbhoy, J Corry Practical radiation oncology 3 (4), e187-e194, 2013 | 16 | 2013 |
| Identifying barriers to accrual in radiation oncology randomized trials JM Laba, S Senan, D Schellenberg, S Harrow, L Mulroy, S Senthi, ... Current Oncology 24 (6), 524-530, 2017 | 15 | 2017 |
| Surgery for early-stage lung cancer: post-operative 30-day versus 90-day mortality and patient-centred care. S Senthi, S Senan European Journal of Cancer (Oxford, England: 1990) 50 (3), 675-677, 2013 | 15 | 2013 |
| Identifying optimal clinical scenarios for synchrotron microbeam radiation therapy: A treatment planning study LML Smyth, LR Day, K Woodford, PAW Rogers, JC Crosbie, S Senthi Physica Medica 60, 111-119, 2019 | 13 | 2019 |
| Investigating strategies to reduce toxicity in stereotactic ablative radiotherapy for central lung tumors S Senthi, M Dahele, BJ Slotman, S Senan Acta Oncologica 53 (3), 330-335, 2014 | 13 | 2014 |
| Limiting the risk of cardiac toxicity with esophageal-sparing intensity modulated radiotherapy for locally advanced lung cancers K Woodford, V Panettieri, JD Ruben, S Senthi Journal of Thoracic Disease 8 (5), 942, 2016 | 12 | 2016 |
